ATE433111T1 - Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren - Google Patents

Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren

Info

Publication number
ATE433111T1
ATE433111T1 AT05797071T AT05797071T ATE433111T1 AT E433111 T1 ATE433111 T1 AT E433111T1 AT 05797071 T AT05797071 T AT 05797071T AT 05797071 T AT05797071 T AT 05797071T AT E433111 T1 ATE433111 T1 AT E433111T1
Authority
AT
Austria
Prior art keywords
invasiveness
aggressiveness
marker
vimentin
invasivity
Prior art date
Application number
AT05797071T
Other languages
English (en)
Inventor
Ali Bouamrani
Emmanuel Gay
Jean-Paul Issartel
Francois Berger
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE433111T1 publication Critical patent/ATE433111T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
AT05797071T 2004-09-17 2005-09-15 Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren ATE433111T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0409857A FR2875601B1 (fr) 2004-09-17 2004-09-17 Vimentine phosphorylee comme marqueur de l'agressivite et/ou l'invasivite des tumeurs
PCT/EP2005/054598 WO2006030023A1 (fr) 2004-09-17 2005-09-15 Vimentine phosphorylée comme marqueur de l'agressivité et/ou l'invasivité des tumeurs

Publications (1)

Publication Number Publication Date
ATE433111T1 true ATE433111T1 (de) 2009-06-15

Family

ID=34953933

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05797071T ATE433111T1 (de) 2004-09-17 2005-09-15 Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren

Country Status (7)

Country Link
US (1) US20070265185A1 (de)
EP (1) EP1789802B1 (de)
AT (1) ATE433111T1 (de)
DE (1) DE602005014789D1 (de)
ES (1) ES2326987T3 (de)
FR (1) FR2875601B1 (de)
WO (1) WO2006030023A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2374450T3 (es) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina.
EP2134860A1 (de) * 2007-04-13 2009-12-23 OSI Pharmaceuticals, Inc. Biologische marker als prädiktoren der antikrebsreaktion auf kinasehemmer
US8048621B2 (en) * 2007-10-03 2011-11-01 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US7939272B2 (en) * 2007-10-03 2011-05-10 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110171124A1 (en) * 2009-02-26 2011-07-14 Osi Pharmaceuticals, Inc. In situ methods for monitoring the EMT status of tumor cells in vivo
AU2011223655A1 (en) * 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013151314A1 (ko) * 2012-04-03 2013-10-10 연세대학교 산학협력단 비멘틴을 포함하는 탈모 억제 또는 발모 촉진용 조성물
EP2964672B1 (de) * 2013-03-05 2019-10-09 Board of Regents, The University of Texas System Spezifisches erkennungswerkzeug für mesenchymale und epithel-mesenchymal transformierte zirkulierende tumorzellen
US20170307615A1 (en) * 2014-09-24 2017-10-26 Geisinger Health System Immunohistochemistry Quality Management Program Using Cultured Cell Lines for Tissue Microarray (TMA) Blocks
EP3387430A4 (de) * 2015-12-11 2019-08-14 Expression Pathology, Inc. Srm/mrm-tests
CN113564172A (zh) * 2021-06-30 2021-10-29 优葆优保健康科技(宁波)有限公司 一种液体活检肿瘤细胞dna适配体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3829226B2 (ja) * 1999-07-07 2006-10-04 独立行政法人理化学研究所 ビメンチンの切断産物に対する抗体
AU2003228225B2 (en) * 2002-03-01 2010-05-13 Roger Williams Hospital SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20060099142A1 (en) * 2002-03-14 2006-05-11 Delaney Allen D Cancer associated araf1 protein kinase and its uses

Also Published As

Publication number Publication date
ES2326987T3 (es) 2009-10-22
FR2875601B1 (fr) 2007-04-13
EP1789802A1 (de) 2007-05-30
EP1789802B1 (de) 2009-06-03
US20070265185A1 (en) 2007-11-15
FR2875601A1 (fr) 2006-03-24
WO2006030023A1 (fr) 2006-03-23
DE602005014789D1 (de) 2009-07-16

Similar Documents

Publication Publication Date Title
ATE433111T1 (de) Phosphorylierte vimentin als marker für die aggressivität und /oder invasivität von tumoren
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
WO2006017150A3 (en) Identification of markers in lung and breast cancer
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
WO2005123993A3 (en) Phage microarray profiling of the humoral response to disease
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
EA200601433A1 (ru) Способы и композиции для лечения опухолей и метастазирования
WO2003083096A3 (en) Cancer associated protein kinases and their uses
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
DE602006016567D1 (de) Reagenzien und verfahren zur verwendung bei der diagnose, klassifizierung und behandlung von krebs
WO2006095086A8 (fr) Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
CR9100A (es) Metodos y sistemas para el pronostico y tratamiento de tumores solidos
WO2002010436A3 (en) Prognostic classification of breast cancer
ATE346301T1 (de) Diagnose von krebsstadium oder aggressivität
DE60016548D1 (de) Snail, neuer marker für die entwicklung von tumoren und zielprotein neuer antitumoraler verbindungen
DE50311312D1 (de) Verfahren zum untersuchen von körperflüssikeiten auf krebszellen sowie entsprechende analysekits
EP1377596A4 (de) Ttk in der diagnose und als therapeutisches target bei krebs
WO2004031231A3 (en) Genes and polypeptides relating to prostate cancers
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2003073821A3 (en) Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties